TY - JOUR
T1 - The use of combination lipid therapy in a county health system
AU - Pio, Margaret Youngmi
AU - Piszczor, Erin Marie
AU - Quinones, Marissa Escobar
AU - Boatright, Steven Micheal
AU - Chow, Diem Hong
AU - Hulstein, Jeffrey Lynn
AU - Moss, Elizabeth
AU - Mathew, Annie Chathanatt
AU - Budhwar, Nitin
PY - 2012/1/1
Y1 - 2012/1/1
N2 - Background: With the paucity of clinical outcomes trials and guidelines to make compelling recommendations regarding the treatment of dyslipidemia beyond statin monotherapy, we present a descriptive analysis of the combination lipid-lowering therapies being used at a large county hospital system. Objective: To provide a descriptive evaluation of the comparative effectiveness and safety of various combination lipid therapies in conjunction with a statin. Methods: Patients of a county health system who received at least 3 months of combination lipid therapy in conjunction with a statin during a 1-year period were eligible for inclusion in this retrospective chart review. The main outcome was a descriptive analysis of the comparative effectiveness among combination lipid therapies, as evidenced by fasting lipid panels. Results: A total of 834 patients were included in the analysis. Approximately 88% were on 1 additional lipid-modifying agent beyond a statin; 2 or 3 additional medications were much less common. Fish oils and fibrates were the most common nonstatin agents used, comprising approximately 85% of the combination therapies. Approximately 17% of patients had all 4 lipids at goal. A majority of patients were at goal for low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol (non-HDL-C), and total cholesterol, but a large proportion were not at goal for HDL-C and triglycerides. No statistically significant differences were found among therapies for effectiveness related to lipid goals, medication adherence, or safety. The chart review did not find an appreciable number of adverse events. The overall adherence rate was subpar at 56% and varied modestly among treatments. Conclusions: This retrospective analysis found no significant differences in effectiveness, adherence, and safety among the combination lipid therapies used in a county health system. Further research is warranted to elucidate the recommended approach to using combination lipid therapies.
AB - Background: With the paucity of clinical outcomes trials and guidelines to make compelling recommendations regarding the treatment of dyslipidemia beyond statin monotherapy, we present a descriptive analysis of the combination lipid-lowering therapies being used at a large county hospital system. Objective: To provide a descriptive evaluation of the comparative effectiveness and safety of various combination lipid therapies in conjunction with a statin. Methods: Patients of a county health system who received at least 3 months of combination lipid therapy in conjunction with a statin during a 1-year period were eligible for inclusion in this retrospective chart review. The main outcome was a descriptive analysis of the comparative effectiveness among combination lipid therapies, as evidenced by fasting lipid panels. Results: A total of 834 patients were included in the analysis. Approximately 88% were on 1 additional lipid-modifying agent beyond a statin; 2 or 3 additional medications were much less common. Fish oils and fibrates were the most common nonstatin agents used, comprising approximately 85% of the combination therapies. Approximately 17% of patients had all 4 lipids at goal. A majority of patients were at goal for low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol (non-HDL-C), and total cholesterol, but a large proportion were not at goal for HDL-C and triglycerides. No statistically significant differences were found among therapies for effectiveness related to lipid goals, medication adherence, or safety. The chart review did not find an appreciable number of adverse events. The overall adherence rate was subpar at 56% and varied modestly among treatments. Conclusions: This retrospective analysis found no significant differences in effectiveness, adherence, and safety among the combination lipid therapies used in a county health system. Further research is warranted to elucidate the recommended approach to using combination lipid therapies.
UR - http://www.scopus.com/inward/record.url?scp=84872369734&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84872369734&partnerID=8YFLogxK
U2 - 10.1177/875512251202800602
DO - 10.1177/875512251202800602
M3 - Article
AN - SCOPUS:84872369734
SN - 8755-1225
VL - 28
SP - 227
EP - 233
JO - Journal of Pharmacy Technology
JF - Journal of Pharmacy Technology
IS - 6
ER -